STOCKS TELEGRAPH

Tag: NASD:CELU

  • After-Market Momentum: Celularity (CELU) Shares Climb On Increased Guidance

    After-Market Momentum: Celularity (CELU) Shares Climb On Increased Guidance

    Celularity Inc. (NASDAQ: CELU) experienced significant stock momentum last Friday, with its shares climbing 7.04% after hours to $3.80, following a regular-session increase of 14.89%, closing at $3.55. The surge follows CELU’s announcement to raise its net sales guidance for the full year 2024.

    Revised Revenue Projections Reflect Biomaterial Sales Growth

    Celularity revised its 2024 revenue expectation from the previously stated range of $50 million to $56 million to an updated estimate of $54 million to $60 million in response to higher anticipated sales. This change coincides with higher-than-expected sales of its advanced biomaterial products, which are expected to add between $49 million and $54.5 million to the company’s yearly sales numbers. Biobanking services are also expected to contribute between $5.0 million and $5.5 million.

    Record Sales Performance Drives Optimism

    October marked a milestone for Celularity with its highest single-month net sales projections, estimated between $8.3 million and $8.9 million. For the ten months ending October 31, 2024, expected net sales reached $44.4 million, comprising $40.2 million from advanced biomaterial products and $4.2 million from biobanking. A substantial part of this sales growth is attributed to Celularity’s newly launched Rebound product, which alone is projected to contribute approximately $9 million to total sales.

    Strong Quarterly Results and Product Demand Bolster Outlook

    Confidence in CELU’s updated full-year projection has been strengthened by the company’s strong second and third quarter results. Rebound, a new product in Celularity’s line of placental-derived bios material solutions, has demonstrated high demand, setting the business up for further growth in the coming quarters. Additionally, Celularity keeps creating next-generation biomaterials, broadening its range of products in the quickly developing domains of cellular and regenerative medicine.

    A Strategic Plan for Further Development in 2025

    Looking ahead, Celularity aims to capitalize on its unique business model, extensive technical infrastructure, and proprietary assets. With a solid commercial foundation, the company is well-positioned to leverage its growing market traction as it advances into 2025 and beyond, remaining at the forefront of innovations in biomaterials and regenerative therapies.

  • Stock Market Resilience: Celularity Inc’s (CELU) Remarkable Turnaround

    Stock Market Resilience: Celularity Inc’s (CELU) Remarkable Turnaround

    During Tuesday’s extended trading session, Celularity Inc. (NASDAQ: CELU) saw a notable uptick in its stock price, gaining 23.57 percent to $7.23 per share. In contrast to CELU’s performance during the regular session, which saw a 15.30% loss and close at $5.89, the stock saw a rise in value as traders anticipated a noteworthy development.

    Dr. Robert Hariri, M.D., Ph.D., the founder and CEO of Celularity (CELU), will deliver the keynote speech at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

    Dr. Hariri’s keynote address, “Prospects of Cell and Immunotherapy: From Oncology to Neurodegenerative Pathologies,” will examine the wide range of uses for cellular immunotherapy, extending beyond oncological settings to include potential applications in neuroinflammatory and degenerative diseases such as multiple sclerosis and Parkinson’s disease.

    Additionally, Dr. Hariri will participate in two other keynote panel discussions during the Congress: the first on March 14, focusing on the “Emergence of Neurotech: Convergence of Cellular Therapy, Medical Devices, and Policy,” and the second on March 16, exploring the intersection of “Cancer, Neurodegenerative Ailments, and Cellular Interventions.”

    Within the rapidly evolving landscape of cellular medicine, Celularity is dedicated to advancing transformative therapies for individuals afflicted with neurological ailments, leveraging its proprietary technology platform, which harnesses placental-derived cells, biological materials, and by-products.

    Celularity has conducted extensive research in neuroinflammatory conditions, including multiple sclerosis, and has investigated the potential of cellular and regenerative therapies in addressing age-related cognitive decline.

    Given the collaborative endeavors facilitated by the SBMT and World Brain Mapping Foundation (WBMF), fostering synergy between academia and industry while presenting viable commercial and investment prospects, the Annual World Congress serves as an ideal forum for discourse on our ongoing research endeavors.

    The trajectory of cellular and regenerative medicine is poised for substantial evolution through its convergence with nanotechnology, predictive modeling, advanced devices, imaging techniques, AI integration, and the advent of augmented and virtual reality applications.

    Guided by Dr. Hariri’s visionary leadership, Celularity is steadfast in its commitment to advancing the frontiers of cellular therapeutics, emerging as a frontrunner in this transformative domain.

  • Celularity (CELU) Stock Suffered A Setback

    Celularity (CELU) Stock Suffered A Setback

    Celularity Inc. (Nasdaq: CELU) experienced a notable setback, witnessing a 6.71% decline in its stock price, culminating in a closing figure of $0.2112 during the previous trading session.

    Of equal significance, the trading volume of Celularity stock on the day significantly undershot the established average, recording a mere 0.26 million shares traded, in contrast to the customary daily average of 0.56 million shares.

    This decline in CELU stock value can be directly attributed to an internal transaction wherein a prominent stakeholder divested approximately 55% of their holdings in the company.

    Sorrento Therapeutics, Inc. holds a substantial 10% stake in Celularity (CELU).

    The most recent insider transaction involving Sorrento took place on October 5, 2023, during which Sorrento proceeded to sell a substantial 6,307,158 shares of CELU’s Class A Common Stock, leading to a reduction of their ownership stake by more than 55%. Consequently, Sorrento’s current holdings in CELU amount to 5.05 million shares.

    Celularity is a prominent biotechnology enterprise specializing in the advancement of allogeneic cell therapies and cutting-edge biomaterial products.

    Notably, CELU has recently embarked on a protracted Research Collaboration Services Agreement with the esteemed Regeneron Pharmaceuticals. This strategic partnership is aimed at bolstering Regeneron’s research endeavors in the realm of allogeneic cell therapy.

    The initial emphasis of this agreement is centered on the exploration of a specialized allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy, an intellectual property of Regeneron. This therapeutic approach is meticulously engineered to augment proliferation and potency in combating solid tumors.

    The research will be conducted at CELU’s state-of-the-art facility, which is conveniently situated in Florham Park, New Jersey. However, financial particulars of this collaboration remain undisclosed.

    This collaborative alliance with Regeneron signifies a significant milestone for Celularity, underscoring its prowess in the domain of cellular therapies, particularly in the domain of CAR-T cell engineering.

    It paves the way for potential future collaborations within the industry, capitalizing on CELU’s exceptional cell therapy infrastructure and capabilities.

    CELU management has long held a deep respect for the outstanding scientific heritage of Regeneron which resulted in them eagerly welcome the opportunity to cooperate with a global leader in groundbreaking pharmaceutical innovation.